Cholangiocarcinoma—with a growing incidence rate and poor prognosis—is not an uncommon cancer. Molecular profiling can reveal actionable aberrations in at least a third of the tumors. This is especially so in the case of intrahepatic cholangiocarcinoma (ICC), where mutations in the isocitrate dehydrogenase 1 and 2 genes (IDH1/2) make up 15%–20% of these tumors. IDH1/2 mutant ICC is a rare disease that has not been adequately reported. To expand the spectrum of findings seen in these patients, we present a single institution case series.
Methods and results
We descriptively characterize the clinical, radiological, and histopathological findings of 12 such patients. IDH1/2 mutant ICC was found in elderly women, with two-thirds of patients having additional co-mutations. Anecdotally, patients who did receive systemic and/or locoregional therapies had long-term durable outcomes.
Conclusion
Our findings indicate an increasing need to personalize an approach for these patients with specific molecular alterations. With the advent of the IDH1 inhibitor ivosidenib and other inhibitors in this space, IDH1/2 mutation have both prognostic and predictive value. Our series builds upon the patterns and findings seen in these patients.
LoweryMAPtashkinRJordanE, et al.Comprehensive molecular profiling of intra- and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin Cancer Res. 2018;24(17):4154–4161. doi: https://doi.org/10.1158/1078-0432.CCR-18-0078
NakamuraHAraiYTotokiY, et al.Genomic spectra of biliary tract cancer. Nat Genet. 2015;47(9):1003–1010. doi: https://doi.org/10.1038/ng.3375
5.
SalatiMCaputoFBaldessariC, et al.IDH Signalling pathway in cholangiocarcinoma: from biological rationale to therapeutic targeting. Cancers. 2020;12(11):3310. doi: https://doi.org/10.3390/cancers12113310
6.
WangTDrillEVakianiE, et al.Distinct histomorphological features are associated with IDH1 mutation in intrahepatic cholangiocarcinoma. Hum Pathol. 2019;91:19–25. doi: https://doi.org/10.1016/j.humpath.2019.05.002
MondesirJWillekensCTouatMde BottonS. IDH1 And IDH2 mutations as novel therapeutic targets: current perspectives. J Blood Med. 2016;7:171–180. doi: https://doi.org/10.2147/JBM.S70716
9.
CairnsRAHarrisISMakTW. Regulation of cancer cell metabolism. Nat Rev Cancer. 2011;11(2):85–95. doi: https://doi.org/10.1038/nrc2981
10.
DangLWhiteDWGrossS, et al.Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739–744. doi: https://doi.org/10.1038/nature08617
11.
BorgerDRTanabeKKFanKC, et al.Frequent mutation of isocitrate dehydrogenase (IDH)1 and IDH2 in cholangiocarcinoma identified through broad-based tumor genotyping. Oncologist.2012;17(1):72–79. doi: https://doi.org/10.1634/theoncologist.2011-0386
12.
BoscoeANRollandCKelleyRK. Frequency and prognostic significance of isocitrate dehydrogenase 1 mutations in cholangiocarcinoma: a systematic literature review. J Gastrointest Oncol. 2019;10(4):751–765. https://jgo.amegroups.org/article/view/28868
13.
GoyalLGovindanAShethRA, et al.Prognosis and clinicopathologic features of patients with advanced stage isocitrate dehydrogenase (IDH) mutant and IDH wild-type intrahepatic cholangiocarcinoma. Oncologist.2015;20(9):1019–1027. doi: https://doi.org/10.1634/theoncologist.2015-0210
BartoliniIRisalitiMFortunaL, et al.Current management of intrahepatic cholangiocarcinoma: from resection to palliative treatments. Radiol Oncol. 2020;54(3):263–271. doi: https://doi.org/10.2478/raon-2020-0045
ConwayAMMorrisGCSmithS, et al.Intrahepatic cholangiocarcinoma hidden within cancer of unknown primary. Br J Cancer. 2022;127(3):531–540. doi: https://doi.org/10.1038/s41416-022-01824-4
BibeauKBachiniMLindleyABarkeyNMLindseyS. Exploring the diagnostic journey and life impact of patients with cholangiocarcinoma (CCA): results from a large patient survey in the United States. J Clin Oncol. 2021;39(3_suppl):277–277. doi: https://doi.org/10.1200/JCO.2021.39.3_suppl.277
20.
KasiPM. Favorable outcomes in FGFR fusion-positive cholangiocarcinomas and evolution on treatment noted on circulating tumor DNA liquid biopsies. Case Rep Oncol. 2020;13(2):941–947.
21.
Popovici-MullerJLemieuxRMArtinE, et al.Discovery of AG-120 (ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Med Chem Lett. 2018;9(4):300–305. doi: https://doi.org/10.1021/acsmedchemlett.7b00421
22.
Abou-AlfaGKMacarullaTJavleMM, et al.Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(6):796–807. doi: https://doi.org/10.1016/S1470-2045(20)30157-1
23.
ZhuAXMacarullaTJavleMM, et al.Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol. 2021;7(11):1669–1677. doi: https://doi.org/10.1001/jamaoncol.2021.3836
24.
LeeJKimSHKangTWSongKDChoiDJangKT. Mass-forming intrahepatic cholangiocarcinoma: diffusion-weighted imaging as a preoperative prognostic marker. Radiology. 2016;281(1):119–128. doi: https://doi.org/10.1148/radiol.2016151781
25.
MaetaniYItohKWatanabeC, et al.MR Imaging of intrahepatic cholangiocarcinoma with pathologic correlation. Am J Roentgenol. 2001;176(6):1499–1507. doi: https://doi.org/10.2214/ajr.176.6.1761499
26.
ChoiSYKimYKMinJH, et al.Added value of ancillary imaging features for differentiating scirrhous hepatocellular carcinoma from intrahepatic cholangiocarcinoma on gadoxetic acid-enhanced MR imaging. Eur Radiol. 2018;28(6):2549–2560. doi: https://doi.org/10.1007/s00330-017-5196-y
27.
MinJHKimYKChoiSY, et al.Differentiation between cholangiocarcinoma and hepatocellular carcinoma with target sign on diffusion-weighted imaging and hepatobiliary phase gadoxetic acid-enhanced MR imaging: classification tree analysis applying capsule and septum. Eur J Radiol. 2017;92:1–10. doi: https://doi.org/10.1016/j.ejrad.2017.04.008
28.
ChoiJYLeeJMSirlinCB. CT And MR imaging diagnosis and staging of hepatocellular carcinoma: part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology. 2014;273(1):30–50. doi: https://doi.org/10.1148/radiol.14132362
KingMJHectorsSLeeKM, et al.Outcomes assessment in intrahepatic cholangiocarcinoma using qualitative and quantitative imaging features. Cancer Imag. 2020;20(1):43. doi: https://doi.org/10.1186/s40644-020-00323-0
31.
GrecoFASpigelDRYardleyDAErlanderMGMaXJHainsworthJD. Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction. Oncologist.2010;15(5):500–506. doi: https://doi.org/10.1634/theoncologist.2009-0328
AbbruzzeseJLAbbruzzeseMCLenziRHessKRRaberMN. Analysis of a diagnostic strategy for patients with suspected tumors of unknown origin. J Clin Oncol. 1995;13(8):2094–2103. doi: https://doi.org/10.1200/JCO.1995.13.8.2094
34.
KerrSESchnabelCASullivanPS, et al.Multisite validation study to determine performance characteristics of a 92-gene molecular cancer classifier. Clin Cancer Res. 2012;18(14):3952–3960. doi: https://doi.org/10.1158/1078-0432.CCR-12-0920
35.
ThomasSPJacobsonLBraitehFS, et al.Molecular diagnosis with the 92-gene assay (92-GA) and decision-impact on treatment: final results from a prospective, multi-disciplinary study. J Clin Oncol. 2015;33(15_suppl):e15206–e15206. doi: https://doi.org/10.1200/jco.2015.33.15_suppl.e15206
36.
PashtoonMurtaza KasiLiMaKaiTreuner, et al.Integration of molecular cancer classification and NGS to identify metastatic patients eligible for IDH inhibitors. J Clin Oncol [Internet]. 2022;40:647–647. https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.4_suppl.647
37.
ModyKKasiPMYangJ, et al.Circulating tumor DNA profiling of advanced biliary tract cancers. JCO Precis Oncol. 2019;3:1–9. doi: https://doi.org/10.1200/PO.18.00324
38.
ChengMLPectasidesEHannaGJParsonsHAChoudhuryADOxnardGR. Circulating tumor DNA in advanced solid tumors: clinical relevance and future directions. CA Cancer J Clin. 2021;71(2):176–190.
39.
LapinMHuangHJChaganiS, et al.Monitoring of dynamic changes and clonal evolution in circulating tumor DNA from patients with IDH-mutated cholangiocarcinoma treated with isocitrate dehydrogenase inhibitors. JCO Precis Oncol. 2022;6:e2100197. doi: https://doi.org/10.1200/PO.21.00197
40.
AguadoEAbou-AlfaGKZhuAX, et al.IDH1 Mutation detection in plasma circulating tumor DNA (ctDNA) and association with clinical response in patients with advanced intrahepatic cholangiocarcinoma (IHC) from the phase III ClarIDHy study. J Clin Oncol. 2020;38(15_suppl):4576–4576. doi: https://doi.org/10.1200/JCO.2020.38.15_suppl.4576
41.
MellinghoffIKvan den BentMJBlumenthalDT, et al.Vorasidenib in IDH1- or IDH2-mutant low-grade glioma. N Engl J Med. 2023;389(7):589–601. https://pubmed.ncbi.nlm.nih.gov/37272516/
